EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Capitalizing Innovation and Reversing It: Mandatory R&D Tax Amortization, Cash-Tax Drains, and Corporate Investment Across the 2022–2025 U.S. Policy Cycle

Natalie Goh, Farhod Rakhimov, Pavel Rogovtsev

Commentary and Critique · 15.11.2026 · 12

DOI: 10.62432/appe.cc.2026.12.51 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Commentary and Critique, online erschienen am 15.11.2026. Verfasst von Natalie Goh und 2 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

When corporate tax statutes defer immediate expensing of intangible investment into multi-year amortization and subsequently restore expensing, user-cost theory predicts a two-sided liquidity pulse concentrated among taxable research-intensive firms. We evaluate this timing-wedge hypothesis across the 2022–2024 mandatory capitalization of research and experimental expenditures under Internal Revenue Code Section 174 and the 2025 domestic expensing restoration under Section 174A. From 4,662 U.S.-incorporated non-financial, non-utility annual corporate filers (40,292 annual periods observed in filings submitted through November 12, 2026), we construct an accounting-corroborated continuous research panel of 586 firms (4,688 firm-years) that eliminates reverse-merger balance-sheet mismatches, alongside an 802-firm date-matched comparison panel. Among firms with positive pre-policy operating income (N = 961, 153 firms, 12 two-digit industries), the conditional slope of net cash income taxes over beginning assets on pre-policy research intensity is +0.0527 during mandatory amortization (SE = 0.0519; restricted wild cluster bootstrap p = 0.2852) and +0.0140 during initial 2025 restoration (SE = 0.0417; bootstrap p = 0.7021), yielding an imprecise reversal contrast of -0.0387 (SE = 0.0357; bootstrap p = 0.2112); omitting a single extreme-hat-value medical-instruments issuer raises the amortization slope to +0.1043 (SE = 0.0219; bootstrap p = 0.0660) and the 2025 slope to +0.0509, while revenue-scaled (+0.1326, bootstrap p = 0.012) and pre-refund gross (+0.1094, bootstrap p = 0.032) cash-tax slopes are positive. Exact unclipped accounting decompositions show that the cash-less-accrued tax wedge widens by +0.1444 in amortization and +0.1575 in 2025 (baseline winsorized slopes +0.1305, bootstrap p = 0.2425, and +0.1329, bootstrap p = 0.0208, or +1.31 and +1.33 percentage points of assets per 10-percentage-point higher research intensity), reflecting positive contemporaneous-income-adjusted cash-tax slopes (+0.0916 and +0.0938) alongside post-2020 earnings mean reversion in book tax accruals, whereas current federal tax expense exhibits a triple-difference reversal contrast of -0.0557 (SE = 0.0194; bootstrap p = 0.020; N = 1,906). Post-2021 research (-0.1682) and capital-expenditure (-0.0324) slopes follow pre-policy upward trends, attenuate under a 2016–2017 exposure anchor (-0.0503, N = 1,216), and show a positive low-cash research interaction (+0.2419, bootstrap p = 0.044), consistent with consolidated jurisdictional aggregation and mid-year enactment timing attenuating observable statutory tax-shield shocks.

Zitieren

APA

Goh, N., Rakhimov, F., & Rogovtsev, P. (2026). Capitalizing Innovation and Reversing It: Mandatory R&D Tax Amortization, Cash-Tax Drains, and Corporate Investment Across the 2022–2025 U.S. Policy Cycle. Commentary and Critique, 12. https://doi.org/10.62432/appe.cc.2026.12.51

Vancouver

Goh N, Rakhimov F, Rogovtsev P. Capitalizing Innovation and Reversing It: Mandatory R&D Tax Amortization, Cash-Tax Drains, and Corporate Investment Across the 2022–2025 U.S. Policy Cycle. Commentary and Critique. 2026;12. doi:10.62432/appe.cc.2026.12.51

BibTeX
@article{Goh2026,
  author = {Goh, Natalie and Rakhimov, Farhod and Rogovtsev, Pavel},
  title = {Capitalizing Innovation and Reversing It: Mandatory R&D Tax Amortization, Cash-Tax Drains, and Corporate Investment Across the 2022–2025 U.S. Policy Cycle},
  journal = {Commentary and Critique},
  year = {2026},
  volume = {12},
  doi = {10.62432/appe.cc.2026.12.51}
}
Kostenlos starten →